Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

Catheters recalled due to defect—FDA highlights risk of stroke or brain damage
The recall was put in place after a hydrophilic coating was discovered on the inside of the devices. According to the FDA, patients treated with the catheters could face a number of significant risks.
FDA clears TAVR guidewire built with BASILICA in mind
The Telltale system was designed to assist cardiologists when BASILICA is required prior to TAVR.
New technique could help when cardiologists repair 2 leaky heart valves at once
Performing M-TEER and T-TEER on the same patient using a single guide catheter appears to be both safe and effective. Researchers shared their experience with this approach in Circulation: Cardiovascular Interventions.
‘Strongest growth in over a decade’: Heart tech helps Medtronic beat earnings expectations
The company's PFA and TAVR technologies both played key roles in the successful second quarter. In addition, Medtronic expects its place in the renal denervation market to make a major impact going forward.
Did Boston Scientific pull the plug too early on TAVR devices? Cardiologists weigh in
Boston Scientific stopped selling its Acurate TAVR systems after they underperformed in a few key trials and failed to gain FDA approval. Was it the right call?

Catheters recalled due to defect—FDA highlights risk of stroke or brain damage

The recall was put in place after a hydrophilic coating was discovered on the inside of the devices. According to the FDA, patients treated with the catheters could face a number of significant risks.

FDA clears TAVR guidewire built with BASILICA in mind

The Telltale system was designed to assist cardiologists when BASILICA is required prior to TAVR.

An FDA panel will discuss its recommendations related to Abbott's TriClip G4 transcatheter edge-to-edge repair (TEER) system for tricuspid regurgitation.

New technique could help when cardiologists repair 2 leaky heart valves at once

Performing M-TEER and T-TEER on the same patient using a single guide catheter appears to be both safe and effective. Researchers shared their experience with this approach in Circulation: Cardiovascular Interventions.

‘Strongest growth in over a decade’: Heart tech helps Medtronic beat earnings expectations

The company's PFA and TAVR technologies both played key roles in the successful second quarter. In addition, Medtronic expects its place in the renal denervation market to make a major impact going forward.

Boston Scientific ACURATE neo2 aortic valve system self-expanding TAVR valve

Did Boston Scientific pull the plug too early on TAVR devices? Cardiologists weigh in

Boston Scientific stopped selling its Acurate TAVR systems after they underperformed in a few key trials and failed to gain FDA approval. Was it the right call?

Boston Scientific said it initiated the AGENT DCB STANCE trial to assess the safety and effectiveness of the Agent Drug-Coated Balloon (DCB) compared to the standard of care using either percutaneous coronary intervention (PCI) with drug-eluting stents (DES) and/or balloon angioplasty. The trial will enroll more than 1,600 patients and is expected to a primary completion date in 2028.

New physician Medicare payments for the Agent drug-coated balloon set for 2027

Boston Scientific said two category III CPT codes are set to become permanent category I codes for physician payments starting Jan. 1, 2027.

Society of Cardiovascular Angiography and Interventions (SCAI) President Srihari S. Naidu, MD, professor of medicine at New York Medical College, explains the SCAI initiative to improve outcomes in cardiogenic shock by monitoring and lowering patient lactate levels.

SCAI: To improve cardiogenic shock outcomes, reduce lactate levels

SCAI feels this is the best way forward to try lowering mortality rates, but the group is asking cardiologists to help by gathering more data.

Siemens Healthineers and Boston Scientific partner on next-generation intracardiac echo for LAAO

The agreement also will make Boston Scientific the exclusive distributor for the new ICE catheter optimized for left atrial appendage occlusion workflows.